SINOVAC first-half sales rise to $147.1 million

• SINOVAC reported first-half 2026 sales of $147.1 million, up 12.9%, while overseas revenue increased 82.3% to $66.5 million.
• No post-results share-price reaction was available because SINOVAC shares remain halted on Nasdaq under halt code T12.
• SINOVAC plans to pursue WHO prequalification for its newly approved rabies vaccine while advancing five late-stage vaccine candidates.

Sinovac Biotech (NASDAQ:SVA) reported first-half 2026 sales of $147.1 million, up from $130.3 million, while net loss attributable to common shareholders widened to $60.2 million.

Overseas revenue increased 82.3% to $66.5 million and represented 45.2% of total sales, while gross margin improved to 65% from 62.5%.

Gross profit increased to $95.5 million, while R&D expenses fell to $83.2 million and cash plus restricted cash totaled $998.5 million at June 30.

SINOVAC said its newly approved PVRV-SF rabies vaccine and late-stage pipeline could support future commercialization.

Following the announcement the Sinovac Biotech share price was unavailable because SVA remained halted on Nasdaq.

SINOVAC reported 2025 sales of $386 million, including $255.7 million during the second half, as international vaccine demand became a larger contributor to revenue.

The company is advancing HFMD2, HFMD4, PCV13, MCV4 and HmAb-TT, while its earlier overseas expansion included an exclusive Chilean contract covering more than eight million influenza vaccine doses.